12.09.2024 13:35:30
|
Health Canada Approves Merck's Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours
(RTTNews) - Merck & Co Inc. (MRK) on Thursday said that Health Canada has granted approval of Keytruda as a monotherapy to treat patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours.
This approval is based on the results from Phase II KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 studies. The efficacy of Keytruda was investigated in 504 patients with MSI-H or dMMR cancer. In a pooled analysis for adult patients, Keytruda showed an objective response rate (ORR) of 34 percent, including a complete response rate of 11 percent and partial response rate of 23% percent.
Keytruda was first approved in 2014 and is currently used to treat various kinds of cancer across the world including head and neck squamous cell carcinoma, advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, etc.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
14.02.25 |
Verluste in New York: Dow Jones präsentiert sich am Nachmittag schwächer (finanzen.at) | |
14.02.25 |
Freitagshandel in New York: Dow Jones verliert mittags (finanzen.at) | |
13.02.25 |
Handel in New York: Dow Jones beendet den Donnerstagshandel mit Gewinnen (finanzen.at) | |
13.02.25 |
Pluszeichen in New York: Dow Jones präsentiert sich am Nachmittag fester (finanzen.at) | |
13.02.25 |
Aufschläge in New York: Dow Jones am Mittag im Plus (finanzen.at) | |
13.02.25 |
Börse New York in Grün: Dow Jones zum Start des Donnerstagshandels fester (finanzen.at) | |
12.02.25 |
Angespannte Stimmung in New York: Dow Jones zeigt sich zum Handelsstart schwächer (finanzen.at) | |
12.02.25 |
China leaves Merck in need of a new profit injection (Financial Times) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 79,60 | -1,12% |
|